In the News
ICON experts frequently author or contribute to industry trade press.
Filter media articles by either clicking within the ‘Category’ drop-down list, or begin typing which will automatically match to the nearest available category.
-
Assessing The Impact Of MDR & IVDR On Patients
In Diagnostics World's recent article featuring commentary from ICON experts David Novotny, Angela Brown and Nicole Cowan, they discussed the need to assess the impact of MDR/IVDR on patients after the new medical device regulation is established.
-
Standardised eCOA questionnaire library will speed study start-up
An Outsourcing Pharma article on the collaboration of ICON’s Mapi Research Trust and Medidata to develop a global library of pre-configured, pre-approved eCOA questionnaires to accelerate study start-up, which is being described as “a win-win-win” for all involved.
-
-
New Frontiers
Read PharmaTimes recent article, featuring ICON expert Tom O'Leary, as he discusses his take on how the Internet of Medical Things (loMT) is evolving the patient role in pharma.
-
Regulatory bottlenecks mean EU clinicians & patients could lose access to medical devices under new rules
A recent press release by Samedan LTD Pharmaceutical Publishers on ICON’s scheduled presentation to be given at The Medtech Conference 2019, ‘MDR/IVDR – What now?’, during which our experts will discuss the findings of the whitepaper ‘Higher Costs & Bottlenecks’, looking at the future implications of the new MDR/IVDR rules on the EU market.
-
Making a Difference
How can we encourage more women to pursue STEM careers? Read how ICON is playing a part in this recent Conversis article.
-
Hasta la vista, maybe? Terminating the Hollywood view of AI in pharma
In drug development, the success of AI depends on gathering the right data and being able to prove its authenticity when an application is subject to regulatory scrutiny. Read this Pharmaceutical Market Europe (PME) article to explore featured commentary from ICON expert Tom O’Leary on the use of AI in the pharmaceutical sector.
-
The evolution of real world studies
Real world evidence is not a new concept, but its influence on drug development decision-makers continues to increase. ICON expert Bill Row discusses how life sciences companies can maximise the use of real world data to support commercial success in this Pharmaceutical Market Europe (PME) article.
-
The modern marketing maze
Pharma is just beginning to scratch the surface of digital as a means of communicating and interacting with patients. Read ICON expert Chuck Stevens' comments on how he and his team are supporting patient/consumer access in this recent PharmaTimes article.
-
MolecularMD Profiled as CDx Developer Making a Mark
From its inception in 2006, the mission of MolecularMD, an ICON plc company, has been to empower therapeutic/diagnostic co-development with strategies that mitigate risk and that nimbly adapt to accelerated approval timelines. Learn more about what makes MolecularMD recognizable as a leader in companion diagnostics development in Clinical OMICs recent article.
